The impact of illness in patients with moderate to severe gastro-esophageal reflux disease

BMC Gastroenterology

Volumn 5, Issue , 2005, Pages

  El Dika, Samer ^a   Guyatt, Gordon H ^b   Armstrong, David ^b   Degl'innocenti, Alessio ^c   Wiklund, Ingela ^c   Fallone, Carlo A ^d   Tanser, Lisa ^e   van Zanten, Sander Veldhuyzen ^f   Heels Ansdell, Dianne ^b   Wahlqvist, Peter ^c   Chiba, Naoki ^b,g   Barkun, Alan N ^d   Austin, Peggy ^b   Schünemann, Holger J ^b,h,i  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c ASTRAZENECA R AND D   (Sweden)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e ASTRAZENECA   (United Kingdom)

^f DALHOUSIE UNIVERSITY   (Canada)

^g Surrey GI Clinic   (Canada)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR; ENZYME INHIBITOR; PROTON PUMP;

ADULT; AGED; ARTICLE; CANADA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SHORT FORM 36; UNITED STATES; VALIDATION PROCESS; VISUAL ANALOG SCALE; COMPARATIVE STUDY; DRUG ANTAGONISM; HEALTH STATUS; MIDDLE AGED; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SICKNESS IMPACT PROFILE; WORK CAPACITY;

ADULT; AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HEALTH STATUS; HUMANS; MIDDLE AGED; OMEPRAZOLE; PAIN MEASUREMENT; PROTON PUMPS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; WORK CAPACITY EVALUATION;

EID: 26444585643     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-5-23     Document Type: Article

References (41)

1. International Foundation for Functional Gastrointestinal Disorders [http://www.aboutgerd.org]. Access date February 14, 2003
2. Louis E, DeLooze D, Deprez P, Hiele M, Urbain D, Pelckmans P, Deviere J, Deltenre M: Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources. Eur J Gastroenterol Hepatol 2002, 14:279-284.
3. Talley NJ, Boyce P, Jones M: Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998, 42:690-695.
4. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
5. Frank L, Kleinman L, Ganoczy D, McQuaid K, Sloan S, Eggleston A, Tougas G, Farup C: Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000, 45:809-818.
6. Wiklund I, Talley NJ: Update on health-related quality of life in patients with gastroesophageal reflux disease. Expert Review of Pharmacoeconomics & Outcomes Research 2003, 3:341-350.
7. Guyatt G, Montori V, Devereaux P, Schünemann H, Bhandari M: Putting the patient first: In our practice, and in our use of language. ACP Journal Club 2004, 140:A11.
8. Fass F, Fennerty B, Vakil N: Nonerosive reflux disease-current concepts and dilemmas. The Am J Gastroenterol 2001, 96:303-314.
9. Kartman B: Utility and willingness to pay measurements among patients with gastroesophageal reflux disease. Am J Gastroenterol 2001, 96:S38-S43.
10. Ofman JJ: Willingness to pay for improved outcomes in GERD: Response to Bernt Kartman. Am J Gastroenterol 2001, 96:S44-S45.
11. Guyatt GH, Feeny DH, Patrick DL: Measuring health-related quality of life. Ann Intern Med 1993, 118:622-629.
12. Kirshner B, Guyatt G: A methodological framework for assessing health indices. J Chronic Dis 1985, 38:27-36.
13. Guyatt GH, Veldhuyzen Van Zanten SJ, Feeny DH, Patrick DL: Measuring quality of life in clinical trials: a taxonomy and review. CMAJ 1989, 140:1441-1448.
14. Wiklund I, Karlberg J: Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Control Clin Trials 1991, 12:204S-216S.
15. Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A: Importance of sensitivity to change as a criterion for selecting health status measures. Qual Health Care 1992, 1:89-93.
16. Torrance GW, Feeny D: Utilities and quality-adjusted life years. Int J Technol Assess Health Care 1989, 5:559-575.
17. Boyle MH, Torrance GW, Sinclair JC, Horwood SP: Economic evaluation of neonatal intensive care of very-low-birth-weight infants. N Engl J Med 1983, 308:1330-1337.
18. Bennet K, Torrance GW: Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. In Quality of life and pharmacoeconomics in clinical trials Edited by: Spilker B. Lippincott-Raven, Philadelphia; 1996:259.
19. Feeny DH, Torrance GW: Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples. Med Care 1989, 27:S190-204.
20. Green C, Brazier J, Deverill M: Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000, 17:151-65.
21. Bakker C, Rutten M, van Santen-Hoeufft M, Bolwijn P, van Doorslaer E, Bennett K, van der Linden S: Patient utilities in fibromyalgia and the association with other outcome measures. J Rheumatol 1995, 22:1536-1543.
22. Fries JF, Ramey DR: "Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis. J Rheumatol 1997, 24:1697-1702.
23. Juniper EF, Guyatt GH, Feeny DH, Griffith LE, Ferrie PJ: Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J 1996, 10:2285-2294.
24. Schünemann HJ, Griffith L, Stubbing D, Goldstein R, Guyatt GH: A clinical trial to evaluate the measurement properties of 2 direct preference instruments administered with and without hypothetical marker states. Med Decis Making 2003, 23:140-149.
25. Furlong WJ, Feeny DH, Torrance GW, Barr RD: The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001, 33:375-384.
26. Torrance GW, Furlong W, Feeny D, Boyle M: Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 1995, 7:503-20.
27. Schünemann HJ, Armstrong D, Degli'innocenti A, Wiklund I, Fallone C, Tanser L, Heels-Ansell D, El-Dika S, Austin P, Barkun A, Chiba N, Guyatt G: A randomized multi-Center trial to evaluate simple utility elicitation techniques in patients with gastroesophageal reflux disease. Med Care 2004, 42(11):1132-1142.
28. Schünemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH: Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol 2003, 56:1170-1176.
29. Kulich KR, Wiklund I, Junghard O: Factor structure of the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire evaluated in patients with heartburn predominant reflux disease. Qual Life Res 2003, 12:699-708.
30. Talley NJ, Fullerton S, Junghard O, Wiklund I: Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001, 96:1998-2004.
31. Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, Pare P, Chiba N, Leddin DS, Bigard MA, Colin R, Schoenfeld P: Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998:41-9.
32. Wahlqvist P, Carlsson J, Stalhammar NO, Wiklund I: Validity of a Work Productivity and Activity Impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD) - results from a cross-sectional study. Value Health 2002, 5:106-113.
33. Hopman W, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, Joseph L, Brown J, Murray T, Adachi J, Hanley D, Papadimitropoulos E: Canadian normative data for the SF-36 health survey. CMAJ 2000, 163:265-271.
34. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
35. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998, 104:252-258.
36. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, McGlynn EA, Ware JE Jr: Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989, 262:907-913.
37. Stewart AL, Hays RD, Ware JE Jr: The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988, 26:724-735.
38. Morimoto T, Fukui T: Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002, 12:160-178.
39. Post PN, Stiggelbout AN, Wakker PP: The utility of health states after stroke: A systematic review of the literature. Stroke 2001, 32:1425-1429.
40. Ware JE Jr, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A: Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 1995, 33:AS264-279.
41. Borchardt PJ: Employee productivity and gastroesophageal reflux disease: the payer's viewpoint. Am J Gastroenterol 2001, 96:S62-63.